CYP3AP2: Key Enzyme in The CYP3A4 Gene Family (G79424)

Target Name: CYP3AP2

NCBI ID: G79424

CYP3AP2

Other Name(s): Cytochrome P450, family 3, subfamily A, polypeptide 5 pseudogene 2 | cytochrome P450, family 3, subfamily A, polypeptide 5 pseudogene 2 | CYP3A5P2

CYP3AP2: Key Enzyme in The CYP3A4 Gene Family

CYP3AP2, a member of the cytochrome P450 (CYP) gene family, is a pseudogene that encodes a putative cytoplasmic protein with sequence homology to the CYP3A4 gene. CYP3AP2 is expressed in various tissues and cells, including the liver, heart, and brain, and has been implicated in the detoxification and metabolism of a wide variety of drugs, including statins, antidepressants, and many other drugs.

CYP3AP2 is a key enzyme in the CYP3A4 gene family, which is responsible for metabolizing a wide variety of drugs, including many statins, to their active metabolites. The CYP3A4 gene is one of the most widely studied genes in the CYP gene family, and has been shown to be involved in the metabolism of many drugs, including many statins, antidepressants, and other drugs.

CYP3AP2 is a pseudogene that encodes a putative cytoplasmic protein with sequence homology to the CYP3A4 gene. It is expressed in various tissues and cells, including the liver, heart, and brain.

The CYP3AP2 gene was first identified in 1995 and has since been extensively studied. Several studies have shown that the CYP3AP2 gene is involved in the detoxification and metabolism of many drugs, including statins, antidepressants, and other drugs. For example, several studies have shown that individuals with certain genetic variations in the CYP3AP2 gene are more likely to have altered drug metabolism and response to drugs, including statins.

In addition to its role in drug metabolism, CYP3AP2 is also involved in the regulation of cellular processes, including cell signaling, cell growth, and cell death. It is a key regulator of the production of the sex hormone estrogen in the body, and has also been shown to be involved in the regulation of other hormones, including progesterone.

CYP3AP2 is a pseudogene that encodes a putative cytoplasmic protein with sequence homology to the CYP3A4 gene. It is expressed in various tissues and cells, including the liver, heart, and brain.

The CYP3AP2 gene has also been implicated in the development of certain diseases, including cardiovascular disease and diabetes. Several studies have shown that individuals with certain genetic variations in the CYP3AP2 gene are more likely to have an increased risk of developing cardiovascular disease and diabetes, and that these individuals may benefit from drug interactions that can increase the effectiveness of certain drugs.

In conclusion, CYP3AP2 is a pseudogene that encodes a putative cytoplasmic protein with sequence homology to the CYP3A4 gene. It is expressed in various tissues and cells, including the liver, heart, and brain, and is involved in the detoxification and metabolism of many drugs, as well as the regulation of cellular processes and the development of certain diseases. Further research is needed to fully understand the role of CYP3AP2 in the CYP gene family and its potential as a drug target or biomarker.

Protein Name: Cytochrome P450, Family 3, Subfamily A, Polypeptide 5 Pseudogene 2

The "CYP3AP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP3AP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets